Fall River, Massachusetts-based Millstone said it closed the deal on Nov. 14. Terms were not disclosed.
Willington, Connecticut-based MycoScience is an ISO 13485 certified contract manufacturing organization operating out of an FDA-registered facility. The company has more than three decades of experience in medical device and pharmaceutical laboratory testing, environmental testing and related regulatory support services.
“With the acquisition of MycoScience, we can offer our customers more support and better controls around product testing, with a single expert point of contact,” Millstone CEO Karl Neuberger said in a news release. “The more advanced and thorough post-manufacturing and aftermarket services we can offer our customers, the more we can support them in creating and accelerating products that change patients’ lives. This acquisition brings together two companies aligned on commitment to quality, expertise, and outstanding customer service.”
MycoScience’s leadership team, including MycoScience CEO Sarath Koruprolu, will remain with the company.
“Over the last 30 years, MycoScience has helped our customers bring amazing new devices and medicines to market for better patient outcomes,” Koruprolu said in the news release. “Now, as we begin a new chapter with Millstone, we look forward to continuing to apply our expertise to product testing, quality and advancements as a part of the industry partner of choice.”
Privately held Millstone offers customized medical device industry outsourcing solutions to global OEMs as well as emerging growth companies. The company offers advanced inspection, sterile and non-sterile packaging, loaner kit processing and distribution services to device and product manufacturers worldwide.
Millstone recently launched a clean room expansion at its Fall River headquarters two years after expanding the facility by 60,000 square feet. The company also operates a facility in Olive Branch, Mississippi.
